ado-trastuzumab emtansine
View Patient InformationAn antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.
| Synonym: | ado trastuzumab emtansine trastuzumab emtansine trastuzumab-DM1 trastuzumab-MCC-DM1 trastuzumab-MCC-DM1 antibody-drug conjugate trastuzumab-MCC-DM1 immunoconjugate |
|---|---|
| US brand name: | Kadcyla |
| Abbreviation: | T-DM1 |
| Code name: | PRO132365 RO5304020 |
| Chemical structure: | immunoglobulin G1, anti-(human p185neu receptor) (human-mouse monoclonal RhuMab HER2 gamma1-chain), disulfide with human-mouse monoclonal RhuMab HER2 light chain, dimer, tetraamide with N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine |